Inactive Instrument

Novo Nordisk A/S Stock SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT

Equities

NOVOB

DK0060102614

Pharmaceuticals

End-of-day quote SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT
- DKK - Intraday chart for Novo Nordisk A/S

Financials

Sales 2024 * 292B 42.75B 58.4B Sales 2025 * 353B 51.75B 70.68B Capitalization 4,302B 631B 862B
Net income 2024 * 103B 15.13B 20.66B Net income 2025 * 128B 18.79B 25.66B EV / Sales 2024 * 14.8 x
Net Debt 2024 * 21.69B 3.18B 4.34B Net cash position 2025 * 4.33B 635M 867M EV / Sales 2025 * 12.2 x
P/E ratio 2024 *
42.2 x
P/E ratio 2025 *
33.7 x
Employees -
Yield 2024 *
1.21%
Yield 2025 *
1.5%
Free-Float 70.3%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 58 90-12-31
Director of Finance/CFO 53 98-12-31
Chief Tech/Sci/R&D Officer - 15-09-30
Members of the board TitleAgeSince
Director/Board Member 62 15-03-18
Chairman 62 17-03-22
Director/Board Member 68 18-02-28
More insiders
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company